Page last updated: 2024-11-02

oxidopamine and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted

oxidopamine has been researched along with Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted in 1 studies

Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lafreniere, MA1
Powdrill, MH1
Singaravelu, R1
Pezacki, JP1

Other Studies

1 other study available for oxidopamine and Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted

ArticleYear
6-Hydroxydopamine Inhibits the Hepatitis C Virus through Alkylation of Host and Viral Proteins and the Induction of Oxidative Stress.
    ACS infectious diseases, 2016, 11-11, Volume: 2, Issue:11

    Topics: Alkylation; Antiviral Agents; Cell Line, Tumor; Cell Proliferation; Hepacivirus; Hepatitis C; Humans

2016